Efficacy and safety of fecal microbiota transplantation for treatment of ulcerative colitis: A post-consensus systematic review and meta-analysis

Table 1 PubMed search strategy

Query search term
1	Colitis, Ulcerative [Mesh]
2	Ulcerative Colitis [Title/Abstract] OR Inflammatory Bowel Disease, Ulcerative Colitis Type [Title/Abstract]
3	1 OR 2
4	Fecal Microbiota Transplantation [Mesh]
5	Fecal Microbiota Transplant [Title/Abstract] OR Fecal Transplant [Title/Abstract] OR Donor Feces Infusion [Title/Abstract] OR Intestinal Microbiome Transplant [Title/Abstract] OR Intestinal Microbiota Transplantation [Title/Abstract] OR Microbiota Transfer [Title/Abstract] OR Fecal Fecal Transplantation [Title/Abstract]
6	4 OR 5
7	randomized controlled trial [Publication Type] OR randomized [Title/Abstract] OR placebo [Title/Abstract]
8	3 AND 6 AND 7

Table 2 Characteristics of the included studies

Ref.	Study design	Intervention			Outcomes
		FMT		Control mode	CR (n/total)		Adverse events	Follow up (weeks)	Reference standard of CR
		pre-FMT therapy	Delivery route		FMT	Control
Moayyedi et al[7], 2015	Double-blind, RCT	NR	Enema	Water enema	9/36	2/35	5	7	Mayo score ≤ 2, endoscopic Mayo score of 0
Rossen et al[8], 2015	Double-blind, RCT	Bowel lavage	Via naso-duodenal tube	AFM	7/17	5/20	4	12	SCCAI scores ≤ 2, Mayo endoscopic score decrease ≥ 1
Paramsothy et al[15], 2016	Double-blind, RCT	NR	Colonoscopic infusion	NR	18/41	8/40	3	8	Mayo score ≤ 2 points with subscores ≤ 1
Costello et al[16], 2017	Double-blind, RCT	NR	Colonoscopic infusion	AFM	19/35	17/34	5	8	Mayo score of ≤ 2 with an endoscopic Mayo score of ≤ 1
Crothers et al[10], 2018	Double-blind, RCT	7 days of antibiotics	Colonoscopic infusion and daily FMTc	Sham FMT	2/7	0/8	NR	12	> 3 point reduction in Mayo score
Midha et al[14], 2018	Double-blind, RCT	NR	NR	NR	12/14	4/14	0	48	Mayo score = 1
Zhang et al[11], 2019	RCT	Sulfapyridine 0.75 g, qid	Enema	Sulfapyridine 0.75 g, qid	48/50	35/50	9	NR	NR
Kedia et al[13], 2022	Open-labeled RCT	FMT + UC-SAID	Colonoscopic infusion	SMT	21/35	10/31	NR	8	Decline in SCCAI > 3
Tkach et al[12], 2022	RCT	Mesalazine 1 g, tid	Colonoscopic infusion	SMT	21/26	19/27	8	8	Partial Mayo score ≤ 2

NR: No report; AFM: Autologous fecal microbiota; SMT: Standard medical therapy; CR: Clinical remission; SCCAI: Simple clinical colitis activity index; UC-SAID: Ulcerative colitis-specific anti-inflammatory diet.

Table 3 Efficacy and safety data of the included studies

Ref.	Patients		ER		AEs
	FMT (n)	Control (n)	FMT (n)	Control (n)	FMT (n)	Control (n)
Moayyedi et al[7], 2015	36	35	NA	NA	3	2
Rossen et al[8], 2015	17	20	NA	NA	2	2
Paramsothy et al [15],2016	41	40	7	3	2	1
Costello et al [16], 2017	35	34	19	6	3	2
Crothers et al [10], 2018	7	8	3	0	0	0
Midha et al [14], 2018	14	14	8	0	0	0
Zhang et al [11], 2019	50	50	29	15	5	4
Kedia et al [13], 2022	35	31	13	3	NA	NA
Tkach et al [12], 2022	26	27	NA	NA	6	2

Efficacy and safety data of the studies. NA: Not available; ER: Endoscopic remission; AEs: Adverse events.